SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: D.Right who wrote (1133)2/21/1998 10:22:00 AM
From: arnie h   of 2173
 
Dear D. - Thanks for your input about Pramlinitide's weight control result and its potential for type II patients. I also feel that the HDL/LDL ratio result is a positive for the outlook. The science behind this result may steer future developments unrelated to diabetes.
I'm wondering if approval is truly needed for Type II. MD's can use drugs off label, if so desired. With the weight control benefit, a higher HDL/LDL ratio, and 75% of people on the drug feeling it useful, wouldn't some MD's do that? Is there something different about diabetes that precludes this?
I have a hard time getting worked up about potential for rat model work that is at the early stage of orexin. I plan to worry about that in a decade or so.
On TA, I subscribe to the Worden Bros. service. They have 2 proprietary indicators that seem to have some value in assessing whether stocks are ready to move one way or the other. I've seen nothing in either of these recently to suggest anything other than
the trading range we're currently in. I tend to think we'll not see much movement until trial developments are clearer. As a long term investor, I don't get too concerned with background scatter. I fact, in cases like this, it's a positive for me as it allows additional accumulation at low prices.

Have a good weekend yourself,
Arnie
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News